Cover Image
市場調查報告書

Galectin Therapeutics, Inc.:產品平台分析

Galectin Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256009
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
Galectin Therapeutics, Inc.:產品平台分析 Galectin Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 43 Pages
簡介

Galectin Therapeutics, Inc.是致力於開發及商品化纖維症及癌症治療藥的生物科技企業。該公司同時也致力於研究半乳糖凝集素蛋白質,並進行臨床實驗。

本報告提供Galectin Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Galectin Therapeutics, Inc.的基本資料

Galectin Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Galectin Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Galectin Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Galectin Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Galectin Therapeutics, Inc.:藥物簡介

  • GR-MD-02
  • GM-CT-01
  • GM-CT-02
  • GR-MD-01
  • GR-MD-03
  • GR-MD-04
  • Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer

Galectin Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Galectin Therapeutics, Inc.:最近的開發平台趨勢

Galectin Therapeutics, Inc.:暫停中的計劃

Galectin Therapeutics, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • GM-CT-01

Galectin Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07442CDB

Summary

Global Markets Direct's, 'Galectin Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Galectin Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galectin Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Galectin Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Galectin Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Galectin Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Galectin Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Galectin Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Galectin Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Galectin Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galectin Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Galectin Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Galectin Therapeutics, Inc. Snapshot
    • Galectin Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Galectin Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Galectin Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Galectin Therapeutics, Inc. - Pipeline Products Glance
    • Galectin Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Galectin Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Galectin Therapeutics, Inc. - Drug Profiles
    • GR-MD-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GR-MD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Galectin Therapeutics, Inc. - Pipeline Analysis
    • Galectin Therapeutics, Inc. - Pipeline Products by Target
    • Galectin Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Galectin Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Galectin Therapeutics, Inc. - Recent Pipeline Updates
  • Galectin Therapeutics, Inc. - Dormant Projects
  • Galectin Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GM-CT-01
  • Galectin Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Galectin Therapeutics, Inc., Key Information
  • Galectin Therapeutics, Inc., Key Facts
  • Galectin Therapeutics, Inc. - Pipeline by Indication, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Galectin Therapeutics, Inc. - Phase II, 2015
  • Galectin Therapeutics, Inc. - Phase I, 2015
  • Galectin Therapeutics, Inc. - Preclinical, 2015
  • Galectin Therapeutics, Inc. - Discovery, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Target, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Galectin Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Galectin Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Galectin Therapeutics, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Galectin Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Galectin Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top